Ontology highlight
ABSTRACT:
SUBMITTER: Shubrook J
PROVIDER: S-EPMC3411543 | biostudies-other | 2011
REPOSITORIES: biostudies-other
Shubrook Jay J Colucci Randall R Guo Aili A Schwartz Frank F
Clinical medicine insights. Endocrinology and diabetes 20110112
The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxaglipt ...[more]